USP9X-deficient cancer cell lines
JHU REF: [C11655]
Invention novelty: The technology consists of colorectal cancer cell lines possessing a knockout mutation in the USP9X gene with/without an additional deletion of p53.
Value Proposition
The cell lines present an opportunity to study the effect of loss of apoptotic control on colorectal cancer cells. Study of deubiquitinase Ups9X could act as a leap towards understanding apoptotic regulation and potentially lead to new drug targets for cancer.
Technical Details
Johns Hopkins researchers have created novel cell lines by deleting certain genes critical for apoptotic control from cancer cell lines. In this technology, the gene USP9X is knocked out of two colorectal cell lines HCT116 and DLD-1. The gene knockout has been performed by rAAV-mediated homologous recombination. The technology also consists of a double knockout line without USP9X and p53, a tumor suppressor gene.
Looking for Partners: To develop & commercialize the technology as research tool
Stage of Development: Discovery
Patent Status: Tangible Property
Publication(s)/Associated Cases: Cancer Biol Ther. 2012 Nov 1; 13(13): 1319–1324
Categories: research tool, cancer, Cell Line
Keywords: Deubiquitinase, knock-out, apoptosis, colorectal cancer
